We thank the participants for their time; Pfizer, Roche, GlaxoSmithKline,
and Zeneca for providing the drugs; Roche and GlaxoSmithKline for research
grants; D Stürchler, J Handschin, M-L Mittelholzer (all formerly at
Roche) for input in planning the study; G Miller, M Endrich (GlaxoSmithKline),
M Philippi (Pfizer), and J P Fabre (Zeneca) for logistical support; P Culbert
(GlaxoSmithKline, Canada), J-P Fabre (Zeneca, France), and C Taureau (Pfizer)
for continuous monitoring of the quality and stability of the study drugs;
Donna Merullo for assistance in the analysis of the profile of mood states
data; Carmen Schwartz for translating the questionnaires from German to
Hebrew; Roman Lässker for creating the ALLMALPRO (all-malaria-prophylaxis)
web sites; Hans Peter Jauss for doing the figures; Maja Rentsch for data
entry management of the quality of life and adverse events questionnaires;
Nicola Funk for data entry of the profile of moods states; all involved
in recruitment (Zürich: J Jücksel, F P Lücking, L Amsler,
M Funk, M P Stürchler, and A Baños; Munich: M Santos; Basel:
C H Hatz, U Legendre; Tel Hashomer: G Regev-Yochay; Frankfurt: S Franck);
the medical residents at the Zürich satellite medical center on the
Kenyan coast; and Albie deFrey, J Ferreira, and R Ferreira in Kruger
Park for providing a back-up network of doctors in South Africa.